Alexander de Leeuw
Lawyer
Alexander is a lawyer at Brinkhof with extensive litigation experience in complex patent cases before the UPC, the Dutch courts (District Court and Court of Appeal of The Hague), and the European Patent Office. Since his admission in 2015, he has been a lawyer at Brinkhof.
(Inter)national Patent Litigation
Alexander specializes in handling complex national and international patent litigation, with a particular focus on pharmaceutical inventions, medical devices, and consumer goods. He is also frequently involved in the protection of know-how and trade secrets and teaches on this topic at the Vrije Universiteit Amsterdam. Additionally, he regularly advises on regulatory matters, such as marketing authorizations, data and market exclusivity, and orphan drugs.
Experience & ancillary activities
In addition to his litigation practice, Alexander publishes regularly on patent law. He is a recurring author of the Kroniek Intellectuele Eigendom for the Dutch Journal NJB and frequently writes about developments in software patents and artificial intelligence. He is also a co-author of Software Patents Worldwide. Furthermore, Alexander contributes to AIPPI Questionnaires and delivers guest lectures. He is an active member of AIPPI, Young EPLAW, LES, and ARRIGE.
Alexander studied law in Amsterdam (University of Amsterdam), New York (Benjamin N. Cardozo School of Law, Yeshiva University), and Copenhagen (University of Copenhagen). He also completed the Grotius specialization program in Health Law. He was admitted to the bar in 2015.
Some of the cases Alexander de Leeuw has handled:
- Representing Agfa in a UPC case against Gucci concerning a method for inkjet printing on leather.
- Litigating on behalf of Sandoz against the compound patent on enzalutamide owned by Astellas and The Regents of the University of California.
- Also representing Sandoz in litigation over the regulatory protection of DMF by Biogen and the damages resulting from unlawfully preventing generic competition from entering the market.
- Defending The Broad Institute in opposition proceedings concerning a broad patent portfolio related to the groundbreaking CRISPR technology for DNA modification.
- Defending Alvotech in litigation against AbbVie regarding whether applying for a marketing authorization at the EMA without a carve-out for a patented indication of adalimumab constitutes unlawful conduct.
- Representing Boston Scientific in preliminary injunction proceedings against Cook, seeking a cross-border injunction for patent infringement involving endoscopic devices.
- Representing The Dow Chemical Company in litigation up to the Dutch Supreme Court against Organik Kimya regarding seizure and disclosure of evidence in trade secret violations and ensuring confidentiality protection.
